2020년 July 8일 by admin 0 Comments

로킷헬스케어, 바이오전문 글로벌 투자사 드래즈캐피탈 투자 유치

로벌 바이오 전문기업 로킷헬스케어(대표 유석환)가 글로벌 투자 전문 기업 ‘드래즈캐피탈(DRADS Capital)’로부터 투자 유치에 성공했다고 8일 밝혔다.

미국 하버드대학교 신경학과 석좌 교수인 루돌프 탄지 박사(Rudolph Tanzi, Ph.D.)가 이끄는 ‘드래즈캐피탈’은 생명 과학, 바이오테크 및 인공지능에 투자하며, 바이오의학의 경계를 넓히는 데 주력하고 있다. 루돌프 탄지 박사는 미국 매사추세츠 종합병원(MGH) 신경과 부의장이자 2015년 미국 타임지가 선정한 세계에서 가장 영향력 있는 100인에 뽑힌 세계 최고의 과학자 중 한 명이다.

드래즈캐피탈의 관계자는 “로킷헬스케어는 혁신적인 4D 바이오 프린팅 기술 및 응용 프로그램 개발에 중점을 둔 한국의 생명 공학 회사로 ‘노화는 질병’이라는 기본 신념을 통해 맞춤형 장기재생 플랫폼으로 세상을 변화시키는 것을 목표로 하고 있다. 이 신념은 로킷헬스케어의 과학적 노력을 이루는 주요 원동력”이라며 “로킷의 새로운 장기 재생 기술이 상처 치유 분야에서 임상 치료법을 크게 개선할 것이라고 믿고 있다.”라고 말했다.

그는 “최근 미국의 당뇨협회(ADA) 학회지에 실린 로킷헬스케어의 논문은 세계 최초의 멸균 올인원 장기재생기 4D 바이오 프린터 ‘닥터인비보’가 당뇨병성 족부 궤양 치료제로 피부를 재생하기 때문에 다리를 절단할 필요가 없는 방법을 제시하는 등 세계 당뇨병 환자들에게 희망적 소식을 전하고 있다. 로킷헬스케어가 유석환 대표의 지도하에 장기 재생 분야의 큰 진전을 이룰 것으로 확신한다”라고 덧붙였다.

특히, 루돌프 탄지 교수는 “우리는 로킷헬스케어와 재생 바이오 프린팅 기술에 대한 엄청난 약속에 동참하게 되어 기쁘다. 로킷헬스케어는 의료 분야에 혁신적인 변화를 가져올 것” 라고 투자이유를 밝혔다.

로킷헬스케어는 당뇨발재생기술, 장기재생플랫폼과 바이오 안티에이징 첨단기술을 보유한바이오 전문기업으로 내년 상장을 목표하고 있다.

로킷헬스케어 유석환 대표는 “셀트리온헬스케어 최고경영자로서의 경험과 첨단장기재생 기술, 바이오 안티에이징, 세계 최고의 바이오 4D 프린팅 기술 개발을 토대로 최첨단 장기재생 플랫폼과 류마티스, 치매 등 바이오 안티에징 글로벌 시장에 새로운 진단치료 기술을 선보일 것”이라며, “이번 드래즈캐피탈의 투자를 계기로 해당 연구진과의 협력을 통해 세계시장 40조원에 이르는 난치병 영역 당뇨발을 치료하는 당뇨발 재생 치료 플랫폼 DFURegen을 비롯해 안전하고 효과적인 환자 맞춤형 장기재생 및 바이오 안티에이징 시장까지 분야를 확대해 글로벌 혁신 기업으로 성장하도록 노력하겠다”고 말했다.

2020년 July 3일 by admin 0 Comments

[로&스탁] 로킷헬스케어, 바이오 노화억제 오픈 이노베이션 세미나 개최

킷헬스케어가 체내에서 시작하는 재생을 주제로 세미나를 개최한다.

글로벌 바이오 전문기업 로킷헬스케어(대표 유석환)는 오는 8일 코엑스에서 ‘Rejuvenation is in Vivo(체내에서 시작하는 재생)’를 주제로 오픈 이노베이션 세미나를 연다고 3일 밝혔다. 이 자리에서 ▲비만 감소를 위한 새로운 접근 방법, ▲초자연골 재생기술과 이를 응용한 100% 인체적합 필러, ▲세포의 사멸과 재생, ▲인체유래 ECM을 활용한 피부의 재생, ▲디지털 헬스케어 플랫폼 서비스 등의 주제가 발표된다고 회사측은 설명했다.

이 회사는 세미나에서 세포, 연골, 비만, 피부 등 몸의 각 부분의 노화와 재생에 대한 새로운 패러다임을 제시한다. 회사 관계자는 “외부로부터 공급되는 재생이 아닌 인체가 가진 재생능력을 최대화해 노화라는 질병을 치유하고 젊음과 건강을 지켜가는 방안을 제시하게 될 것”이라고 말했다.

이번 세미나는 국내 저명 교수들의 참여로 폭넓은 지식 공유가 가능할 것으로 기대하고 있다. 세포사멸학의 권위자인 고려대 최의주 교수와 노화방지 분자 NAD+전문가 성균관대 류동렬 교수 등이 참여해 세포가 사멸하고 재생되는 과정과 바이오 노화억제에 관한 학술적 근거를 논한다. 초자연골을 활용한 연골의 재생과 바이오필러, 류마티스의 조기 진단을 위한 싱글셀분석과 바이오마커도 발표될 예정이다.

로킷헬스케어는 세미나를 통해 자사 제품과 플랫폼도 선보인다. 비만 감소를 위한 제품 ‘하이비키니’, 획기적인 바이오 노화억제 제품 ‘로킷아메리카 NMN’, 두피 모발 토탈 솔루션 ‘아쿠아 드 폴리’, 인공지능 기반 화장품 큐레이션 서비스인 ‘헤르니에AI’, 유전자 분석에 기반한 디지털 헬스케어 플랫폼을 공개한다.

한편 이 회사는 지난달 장기재생기 닥터인비보4D6(Dr. INVIVO 4D6) 론칭기념 학술 세미나에서 ‘세상이 거절할 수 없는 기술’을 주제로 세계 최초의 인체 장기를 재생 플랫폼 등 새로운 패러다임을 제시한 바 있다. 이번 세미나는 유튜브를 통해 라이브 방송으로도 시청할 수 있다.

2020년 June 30일 by admin 0 Comments

Cartilage Regeneration Platform 1st Webinar: Next Generation of Autologous Therapeutic Solution

ROKIT Open Innovation
Cartilage Regeneration Platform 1st Webinar
Next Generation of Autologous Therapeutic Solution
- 2020. 07. 03. FRI. 08:00 AM (GMT+8) -
OVERVIEW

"Cartilage Regeneration Platform"

Our cartilage regeneration platform is an individually customized
therapeutic solution platform which combines 3D bio-printing technology and tissue engineering.

Check out the webinars for more details.
SPEAKER

Yunsung Cho (Brian)

  • Cartilage & Bio Filler SBU vice-president

Career Highlight

  • IBM Korea – Systems Sales Specialist
  • Teravision inc. CEO
INFORMATION
Subject
Date
Live Platform
Cartilage Regeneration Platform 1st Webinar:
Next Generation of Autologous Therapeutic Solution
2020.07.03. FRI 08:30 AM (GMT+8)
Youtube
PROGRAM
Part 1
The Recent Trend of Cartilage Repair
Part 2
The ROKIT's Technology : Organ Regenerator
VIEW-AGAIN
Please RSVP, we send you Youtube link soon!

Privacy Policy

Collection of Information : Name, Email, Institution, Dept Name Purpose of Collection : Contact Period of Use : In principle, after the purpose of collecting and using personal information is achieved, such information shall be destroyed without delay. However, personal information may be kept for a certain period as specified in the relevant statutes, if it is necessary to preserve it according to the provisions of the relevant statutes, as follows. - Records on consumer complaints or dispute handling : 3 years (Law on Consumer Protection in Electronic Commerce, etc.) - Agree to collect and use of personal information above. (you can inquire after consent)

ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
ROKIT Healthcare INC.

2020년 June 30일 by admin 0 Comments

4-D Human Tissue Engineering with Dr. INVIVO 4D6 🇺🇸

ROKIT Open Innovation
Combining the Bioprinter, Cell Incubator, and Sterilizer All-In-One
4-D Human Tissue Engineering with Dr. INVIVO 4D6
- 2020. 07. 14. TUE. 11:00 AM (EDT) -
OVERVIEW

"Learn more about Dr. INVIVO 4D6"

Achieving the 3-dimensional architecture is just one of several factors to consider in tissue engineering.
Cell environment factors like the incubation temperature, CO2 level,
and humidity are critical for optimal human tissue and organ development.
Moving beyond dispensing cells and biomaterials with multiple printheads,
Dr. INVIVO 4D6 offers an integrated system to meet clinical needs
in human tissue engineering and its translational applications.

Check out the webinars for more details.
SPEAKER

ROKIT HEALTHCARE

co-hosted by Global Dr. INVIVO Partners

  • Swift Scientific (USA)
INFORMATION
Subject
Date
Live Platform
4-D Human Tissue Engineering with Dr. INVIVO 4D6
2020.07.14. TUE 11:00 AM (EDT)
ZOOM
ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
ROKIT Healthcare INC. Da-Yae Lee

2020년 June 30일 by admin 0 Comments

4-D Human Tissue Engineering with Dr. INVIVO 4D6 🇸🇬/🇲🇾

ROKIT Open Innovation
Combining the Bioprinter, Cell Incubator, and Sterilizer All-In-One
4-D Human Tissue Engineering with Dr. INVIVO 4D6
- 2020. 07. 02. THU. 15:00 PM (GMT+8) -
OVERVIEW

"Learn more about Dr. INVIVO 4D6"

Achieving the 3-dimensional architecture is just one of several factors to consider in tissue engineering.
Cell environment factors like the incubation temperature, CO2 level,
and humidity are critical for optimal human tissue and organ development.
Moving beyond dispensing cells and biomaterials with multiple printheads,
Dr. INVIVO 4D6 offers an integrated system to meet clinical needs
in human tissue engineering and its translational applications.

Check out the webinars for more details.
SPEAKER

ROKIT HEALTHCARE

co-hosted by Global Dr. INVIVO Partners

  • Calia Technology (Singapore & Malaysia)
INFORMATION
Subject
Date
Live Platform
4-D Human Tissue Engineering with Dr. INVIVO 4D6
2020.07.02. THU 15:00 PM (GMT+8)
ZOOM
REGISTER
Please RSVP today, we will send you ZOOM link soon!

Privacy Policy

Collection of Information : Name, Email, Institution, Dept Name Purpose of Collection : Contact Period of Use : In principle, after the purpose of collecting and using personal information is achieved, such information shall be destroyed without delay. However, personal information may be kept for a certain period as specified in the relevant statutes, if it is necessary to preserve it according to the provisions of the relevant statutes, as follows. - Records on consumer complaints or dispute handling : 3 years (Law on Consumer Protection in Electronic Commerce, etc.) - Agree to collect and use of personal information above. (you can inquire after consent)

ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
ROKIT Healthcare INC. Da-Yae Lee

2020년 June 30일 by admin 0 Comments

Incubator X Bioprinter X Sterilizer: All-In-One Biofabrication is Medicine’s Next Frontier

ROKIT Open Innovation
Incubator X Bioprinter X Sterilizer
All-In-One Biofabrication is Medicine's Next Frontier
- 2020. 07. 02. THU. 20:30 PM (GMT+3) -
OVERVIEW

"Learn more about Dr. INVIVO 4D6"

Achieving the 3-dimensional architecture is just one of several factors to consider in tissue engineering.
Cell environment factors like the incubation temperature, CO2 level,
and humidity are critical for optimal human tissue and organ development.
Moving beyond dispensing cells and biomaterials with multiple printheads,
Dr. INVIVO 4D6 offers an integrated system to meet clinical needs
in human tissue engineering and its translational applications.

Check out the webinars for more details.
SPEAKER

ROKIT HEALTHCARE

co-hosted by Global Dr. INVIVO Partners

  • BioTrend Medical & International Society for Stem Cells Applications (Turkey)
INFORMATION
Subject
Date
Live Platform
Incubator X Bioprinter X Sterilizer:
All-In-One Biofabrication is Medicine's Next Frontier
2020.07.02. THU 20:30 PM (GMT+3)
ZOOM
ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
ROKIT Healthcare INC. Da-Yae Lee

2020년 June 30일 by admin 0 Comments

로킷헬스케어, 4D 바이오프린팅 당뇨발 재생플랫폼 미국 당뇨학회 게재

▲닥터인비보4D 이미지

킷헬스케어(대표 유석환)가 자사 당뇨성족부궤양의 치료(이하 ‘당뇨발재생치료플랫폼’) 연구 초록이 국제 저명 학술지인 미국당뇨협회(ADA) 학회지에 게재됐다고 30일 밝혔다.

로킷헬스케어에 따르면 4D 바이오 프린팅 당뇨발재생치료플랫폼은 유럽의 첨단재생법에 따라 작년 5월 공식적으로 자가재생치료법으로 기승인 받은 바 있으며 인도, 한국 당뇨발 임상이 성공적으로 진행되고 있다.

또한 로킷헬스케어의 당뇨발재생치료플랫폼은 4D 바이오 프린팅 기술을 활용한 ‘DFURegen’ 솔루션으로 환부에 정확한 모양, 크기를 적용해 치료를 진행하는것으로 알려져 있다.

회사 관계자는 “수개월 동안 치료가 어렵던 당뇨발 대부분의 환자에게서 면역 거부반응 없이 단기간에 내부로부터 혈관 및 피부조직이 재생돼 정상 피부로 완치되는 것을 확인했다”며 “4D 바이오 프린팅을 이용한 당뇨발 치료방법은 첨단과학기술을 이용해 치료 기간과 완치율을 획기적으로 높였다고 평가 받고 있다”고 말했다.

이어 “세계적으로도 처음 시도되는 기술로 전세계 약 4,000만명의 당뇨발 환자와 글로벌 40조원 시장을 겨냥하고 있다”고 덧붙였다.

한편, 이번에 초록이 게재된 학술지는 미국당뇨협회에서 발행하며 이 협회는 지난 80년간 의료계 종사자 20,000명 이상이 참석하는 학회를 매년 개최하고 있다.

2020년 June 29일 by admin 0 Comments

Bioprinted Skin Patches for Diabetic Foot Ulcers Commercialized by Rokit Healthcare

After years of investigating ways to manage treatment for diabetic foot ulcers (DFU), Korean 3D bioprinter manufacturer, Rokit Healthcare finally announced the success of a new DFU regeneration platform based on its 4D bioprinting technology for customized tissue regeneration. This new and alternative method for chronic wound healing promotes a mechanism of skin reconstruction for DFU treatment that was successfully tested on patients and will be globally commercialized this year.

To find an advanced treatment method, particularly for wound healing, Rokit tested the DFU therapy with its own 4D bioprinting system, using a personalized bioink developed with the patient’s own adipose tissue that had no immune rejection.

With diabetes on the rise in most countries, patients require targeted therapies and effective solutions for pain management. Today, over 460 million adults have diabetes, that’s roughly 6% of the global population, and it is expected to reach 700 million patients by 2045. Furthermore, diabetes can damage eyes, kidneys, and nerves, cause heart disease, stroke, and even the need to remove a limb. In fact, diabetic foot ulcerations are one of the most common complications associated with diabetes, as an estimated 50% of diabetic ulcers become infected and could result in amputation.

Rokit’s mission is to decrease the rate of amputation for patients with DFU, by offering safe and effective regenerative therapy based on 4D bioprinting technology. As part of one of their continuing studies, a global Rokit team successfully tested its DFU regeneration platform on patients in India and will continue clinical trials in South Korea, Europe, North America, and East Asia.

The process begins with fat tissue taken from a patient (for example through liposuction), which is then used to prepare an autologous extracellular matrix (ECM) mixture to form a bioink that is loaded into Rokit’s INVIVO 4D bioprinter to produce a dermal patch. The autologous patch is finally implanted at the wound site after the damaged tissue has been removed.

The results of the study, published in the American Diabetes Association‘s journal Diabetes, describe how the autologous ECM patch, applied onto the chronic wound site of DFU patients, resulted in a significant wound size reduction after only a one-time treatment.

During the tests, most of the patients showed complete closure of the wound in only two to five weeks. In fact, after a 14-day skin wound healing process, the treated wound area had more effectively reconstructed epidermal and dermal structures when compared to the non-treated wound areas.

▲ After the process, the treated wound area has more effective reconstructed epidermal and dermal structure compared to the non-treated area (Credit: Rokit Healthcare)

“My team recently focused on skin regeneration, especially for caring diabetic foot ulcers. Using our 4D bioprinting system with patient’s autologous fat tissue, diabetic foot ulcers were successfully healed after getting only one treatment during the clinical trials. Rokit’s DFU regeneration platform will provide a safe, fast, and cost-effective solution for curing diabetic wounds,” said Jeehee Kim, president of Rokit Healthcare’s DFU and Skin Regeneration Strategy Business Unit and author of the published paper.

Currently, diabetic foot ulcers are treated with dressings, negative pressure, and skin grafting, but according to Rokit, these treatments have proven ineffective, costly, and time-consuming for patients, moreover, they do not provide the correct therapeutic approach as regenerative medicine and tissue engineering would. Instead, the company’s alternative treatment solution to promote skin reconstruction, along with its use of biomaterials and bioink designs, can hold a lot of promise for future effective customized 4D bioprinting to regenerate human tissues and organs.

▲ DFU treatment process (Credit: Rokit Healthcare)

To find an advanced medical solution, particularly for diabetic wound healing and skin regeneration, Rokit used its 4D bioprinting platform along with the minimally manipulated autologous fat tissue. According to the company, INVIVO was key to its success, provided a fast regeneration effect and customized treatment that fits the skin loss area.

“Dr. INVIVO is what we believe to be a scientific breakthrough. It’s the world’s first clean bench hybrid 4D bioprinter. When creating a regenerative patch on diabetic foot ulcer patients, Dr. INVIVO plays a mayor role. With its precise and rapid manufacturing capabilities, Dr. INVIVO helps create a personalized therapy solution by building patient specific designs,” explained one of Rokit Healthcare’s R&D engineers, Jaeyong Shin One.

As reported by MK’s Maeil Business Newspaper, Rokit Healthcare has begun commercializing in 48 countries its DFU treatment platform that uses 4D bioprinter Dr. INVIVO. To that end, the company signed a per region export business cooperation agreement and expects the number of sales for this year alone to reach 424 million dollars and well over one billion dollars by 2022. For now, the contract enables commercialization of the platform to India, countries in Europe, Latin America, the Middle East, and North Africa. However, the company already has plans to expand, launching the platform in other regions, like North America, Japan, China, and Australia.

The platform includes all of the procedures required to treat DFU, including 3D scanning of the affected area, diagnosis, bioprinting with personalized bioinks, and a procedure kit. In addition to domestic patents, the company has obtained certifications from the European Medicines Agency (EMA) and is currently undergoing the required procedures from the Food and Drug Administration (FDA) that would allow commercialization in the United States.

The company’s INVIVO bioprinting technology has already been acquired by research labs and institutions in more than 25 countries, specializing in tissue and material engineering, drug testing, 3D tissue, and disease modeling. Dr.INVIVO is the world’s first sterile, all-in-one 4D organ regenerator. Rokit’s autologous skin regeneration procedure using Dr.INVIVO already received regulatory approval for non-advanced therapy medicinal products (ATMP) by the EMA for the treatment of diabetic ulcers, pressure ulcers, scar revision, and burn wounds, meaning immediate access to the operating room.

▲ Dr. INVIVO (Credit: Rokit Healthcare)

“Imagine that you get a 3D bioprinting service in a hospital to renew your damaged body parts. The human body is composed of cells, proteins and extracellular materials that we can also use a bioink to regenerate organs, which means regrowing the injured body back to its original shape and function,” Kim went on. “4D bioprinting technology is the best method to create human organs, such as skin, cartilage and bone tissue. We live in the era of the fourth industrial revolution that will ideally change human lifestyle, including our healthcare service. Now, Rokit Healthcare leads the advanced cutting edge 4D bioprinting technology as a pioneer.”

Ulcer healing usually takes weeks or even months, with many ulcers never healing and resulting in amputations. By promoting mechanisms of skin reconstruction, this alternative method could be essential to reducing the risks associated with DFU’s, as well as help lower therapy costs, and lead to a better quality of life for patients. By attempting to cure the inevitable development of diabetic ulcers, Rokit Healthcare is pioneering the foot regeneration treatment market thanks to its innovative development. However, healing diabetic ulcers is only the beginning, the company’s unique treatment platform is already moving into cartilage regeneration and other skin wounds and disease.

2020년 June 25일 by admin 0 Comments

Rejuvenation is in Vivo

ROKIT OPEN INNOVATION
Rejuvenation is in Vivo
- 2020. 07. 08. WED. 17:00 PM -
초대의 글

"Rejuvenation is in Vivo"

로킷헬스케어는 사람들이 당연하다고 여길 수 있는
장기 노화와 질병 해결을 위한 장기 재생 및 의료 플랫폼을 개발해
인류의 수명을 연장하고 삶의 질을 개선하는 것을 목표로 삼고 있습니다.

ROKIT Open Innovation (Rejuvenation is in Vivo)에서는
로킷헬스케어의 안티에이징 플랫폼들의 연구, 성과들을 공유하고
재생의학과 바이오 분야에서 연구자와 산업 내.외부와의 개방적 혁신을 통해
통찰력, 기술, 플랫폼, 리소스 등을 연결하고자 합니다.

웨비나를 통해 자세한 내용을 확인하세요.
INFORMATION
행사명
Rejuvenation is in Vivo
일시
2020.07.08. 수요일 오후 17:00
대상
로킷헬스케어 유튜브 채널 구독자
안내사항
본 세미나는 Youtube Live를 통해 웨비나가 함께 진행됩니다.
PROGRAM
웨비나 다시보기
기입해주신 분들께 웨비나 다시보기 링크를 이메일로 발송드리며,
추후 보다 유용한 콘텐츠와 정보를 제공해드립니다.

개인정보 수집 및 이용

더 나은 정보 제공을 위한 최소한의 개인정보를 수집하고 이용합니다. 수집된 정보는 정보 제공 외 다른 목적으로 이용되지 않으며, 서비스가 종료되거나 구독을 해지할 경우 즉시 파기됩니다.

ROKIT HEALTHCARE is a 4D Bioprinting and Biotechnology company based in South Korea and is committed to bettering humanity through our contributions to the field of regenerative medicine.
Question
(주)로킷헬스케어 안하영M